单选题
题号 #6528569

根据以下材料,回答题
Patents are supposed to incentivize success.And yet that's not how patent law works today.The courts, Congress and boardrooms are advancing a simple logic that turns the patent system onits head.The consequences are on display in the pharmaceutical industry.For example, a Johnson& Johnson report argues that the cost of a drug should not only reflect research costs related to thatdrug, but also should include expenses from "drug candidates that fail in development".
  But the patent system is designed to reward success.One does not receive a patent for aninvention one tried and failed to create.Similarly, a patent's reward reflects the successfulinvention, rather than compensation for other attempts gone bad.
  Ensuring that rewards cover the costs of failure might appear logical at first glance.Butallowing the patent system to compensate for the cost of failures has a perverse effect, particularlywhen the pharmaceutical industry uses it to lobby for expansion of patent protection.The argumenthas become: We need to hold off competition more, so that we can charge more to compensate forpast failures.But that distorts the purpose of a patent.If patents reward failure, then the more acompany fails, the longer and broader of a monopoly they'll need when they do succeed.
  In a perfect world, one might expect purchasers to create a natural brake on the system.Intheory, one cannot charge a price unless buyers are willing to pay.Health care is a strange market,however.Patients may consume the medication, but doctors are in charge of choosing it, andinsurance pays for much of it.In addition, modem strategic behaviors in the drug approval andreimbursement system can diminish the competition that might otherwise prevent drug companiesfrom raising prices unchallenged.Thus, the normal pressures that would limit prices are dampenedin the market for prescription medicine.
  Incentivizing failure is particularly problematic in light of a historic shift in the pharmaceuticalindustry over the past decade.Faced with stagnating research results, the industry has shifted tooutsourcing innovation.Specifically, the majority of innovation in the industry comes fromacademia or from small life-science companies.Large pharmaceutical companies then shepherd thedrugs through the FDA approval process and into production.And so, at the end of the day, thebig companies--the ones arguing for compensation for failure through hefty patent returns--are notthe ones taking the greatest risks for drug development.Rather, they are gaming the patent system:maintaining high prices and keeping competitors out with patent protections.
  If society actually wanted a patent system that compensates for failure, the dollars would go tothose who make the investment in the research and take the risk of failure--the inventors.None ofthat is happening here.Instead, by passing so little of the profit to those who perform the successfulresearch, the system dilutes the incentive for research.We are not just incentivizing failure, we aresending those dollars to the least inventive part of the innovation chain.
The Johnson & Johnson report is cited to show that

进入在线模考

参考答案

D

答案解析

[信息锁定]文章首三句指出,专利理应激励成功,然而如今专利法的运作方式却并非如此,法院、国会和董事会们正在推行的逻辑意欲完全颠覆专利制度。言外之意即他们意欲激励失败。④句聚焦于这种逻辑给制药行业带来的影响。⑤句援引强生公司报告中的观点“药物的成本不仅要包括此类药物成功开发的研究成本,也要包括开发失败的候选药物的研究成本”。由⑤句句首For example传递的例证逻辑可知,强生公司报告中的观点“药物成本还要覆盖开发失败的药物”恰好是法院、国会和董事会们“颠覆专利制度,意欲奖励失败”逻辑在制药行业的具体表现,由此证实如今专利制度的运用并未能达到其“激励成功”的预期目的.D项正确。
[解题技巧]A、B两项均囿于事例本身,源自强生公司报告,“药物的成功创新历经多次失败”和“制药公司需要在研究方面大量投资”仅为事实描述(论据),而非作者引用该报告的目的(服务于某观点或情况),事例本身并不等同于写作目的。c项将首三句对如今专利法运作方式的批判偷换为对专利法本身的批判,结合后文可知作者支持专利制度“激励成功”的预期目的,其反对的是专利制度被大企业操纵以补偿“失败成本”的现实。

你可能感兴趣的试题

A. supportive.
B.  tolerant.
C. sarcastic.
D.  confused.
A.Big pharma manipulates the patent system to gain a monopoly.
B.  Drug purchasers decide the evolution of the patent system.
C. Drug pricing is based on patients' willingness to pay.
D.  The drug approval system aims to avoid cut-throat competition.
A. has resulted in an innovation stagnation in the drug industry.
B. has caused huge losses for big pharmaceutical companies.
C.poses a serious challenge to the FDA approval process.
D. places the true inventors in a disadvantaged position.
找试题 · 找答案 · 找资料 在线模考